AC Immune SA
PSE Building B - EPFL
Lausanne
CH-1015
Tel: 41-21-693-9121
Fax: 41-21-693-9120
Website: http://www.acimmune.com/
Email: info@acimmune.com
90 articles about AC Immune SA
-
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
-
AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors
10/29/2021
Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization.
-
There were a fair number of clinical trial announcements last week. Here’s a look.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Mixed Bag in Phase II Alzheimer's Trial
8/31/2021
AC Immune and Genentech announced that their Phase II Lauriet trial of semorinemab in mild-to-moderate Alzheimer’s disease hit one of its co-primary endpoints. -
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
-
Clinical Catch-Up: May 17-21
5/24/2021
It was another busy week for clinical trial announcement. Here’s a look. -
Clinical Catch-Up: February 8-12
2/15/2021
It was a busy week for clinical trial announcements and news. Here’s a look. -
Switzerland-based AC Immune SA announced positive interim results from its ongoing Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease.
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
The drug failed to meet its primary efficacy endpoint, as well as two secondary endpoints.
-
Clinical Catch-Up: July 13-17
7/20/2020
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look. -
AC Immune, based in Lausanne, Switzerland, initiated the second highest dosing group in its Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease. The move is based on encouraging interim data from the initial dosing cohort.
-
What is the best way to prevent or even reverse Alzheimer’s disease? That’s the question at the top of many researchers’ minds, especially given all of the recent large Phase 3 failures involving beta-amyloid targeting drugs, the most pursued target to date. This is troubling but not entirely sho...
-
Clinical Catch-Up: September 16-20
9/23/2019
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories. -
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update
8/14/2019
Company Outlines Roadmap to Develop Successful Therapies for Neurodegenerative Diseases Based on its Broad Anti-Tau Clinical Pipeline
-
AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases
8/12/2019
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced a research partnership with leading scientists in the Perelman School of Medicine at the University of Pennsylvania focused on studying the pathological mechanisms of TDP-43 misfolding and aggregation.
-
AC Immune Initiates Ph1b/2a Study of Anti-Phospho-Tau Vaccine in Alzheimer’s Disease
8/1/2019
Clinically advanced vaccine, ACI-35.030, designed to reduce and to prevent the spread and development of Tau pathology
-
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
7/17/2019
Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company